Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19.

Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting.

Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR=1.022, 95%CI 1.007‒1.038 and OR=1.025, 95%CI 1.001‒1.051, respectively), while thromboprophylaxis use was protective (OR=0.199, 95%CI 0.061‒0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR=1.062, 95%CI 1.017-1.109 and OR=2.438, 95%CI 1.023-5.813, respectively).

Conclusions: Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.

Paolo Ghiaand Kostas Stamatopoulos contributed equally to this work.

Scarfò:Octopharma: Speakers Bureau; AbbVie, AstraZeneca, Janssen, Beigene: Honoraria; BeiGene, Janssen: Other: Travel Grant. Cordoba:Janssen: Other: Speaker; Astra Zeneca: Other: Speaker; Lilly: Consultancy; Beigene: Consultancy; Janssen: Consultancy; Astra Zeneca: Consultancy. Doubek:AOP Orphan: Consultancy, Research Funding; AbbVie: Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Honoraria. García-Serra:Novartis: Other: received educational activity; Abbvie: Other: received educational activity. Gomes da Silva:Gilead Genesis: Research Funding; AstraZeneca: Research Funding; Janssen, Gilead Sciences, MSD, Celgene, Roche, Takeda, Novartis, ADC Therapeutics: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau. Hernández-Rivas:Rovi: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Beigene: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; Lilly: Membership on an entity's Board of Directors or advisory committees. Itchaki:AstraZeneca: Consultancy; Abbvie: Consultancy; Janssen: Consultancy. Jaksic:Johnson and Johnson: Speakers Bureau; Abbvie: Speakers Bureau; Astra Zeneca: Consultancy, Speakers Bureau. Janssens:Genmab: Current Employment; Abbvie: Consultancy, Other: Travel Grants, Speakers Bureau; Amgen: Consultancy, Other: travel grants, Speakers Bureau; Astra-Zeneca: Consultancy, Speakers Bureau; Beigene: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Sobi: Consultancy, Speakers Bureau; Sanofi Genzyme: Consultancy, Speakers Bureau; Roche: Consultancy; Celgene: Other: travel grants. Kater:Astra Zeneca, BMS, Roche/Gennetech, Janssen, Abbvie, LAVA: Membership on an entity's Board of Directors or advisory committees; Janssen, LAVA: Patents & Royalties: Pending; Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment. Levin:AbbVie, Roche and Janssen: Other: Travel expenses. Munir:Janssen, AstraZeneca, Alexion, Sobi, Novartis, Roche, Abbvie, Gilead: Honoraria; Janssen, AstraZeneca, Alexion, Abbvie, Novartis, Roche: Membership on an entity's Board of Directors or advisory committees. Pavlovsky:AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Raffo: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Other; AbbVie: Other: Conference; Janssen: Other: Conference; Janssen: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees. Reda:Janssen, Abbive, Astra Zeneca, Beigene: Consultancy. Rigolin:Abbvie: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria; Gilead: Honoraria, Research Funding. Šimkovič:Janssen-Cilag, Gilead, Roche, AstraZeneca, Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grants. Tonino:Roche: Honoraria; Incyte: Honoraria; Takeda: Honoraria. Varettoni:ABBVIE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; ASTRAZENECA: Membership on an entity's Board of Directors or advisory committees; BEIGENE: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; JANNSEN: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses. Visentin:Janssen, Abbvie, CSL Behring, Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Wróbel:GSK: Honoraria; Janssen: Honoraria; Amgen: Honoraria, Research Funding; Takeda: Honoraria; Beigene: Honoraria; Novartis: Honoraria; Abbvie: Honoraria; Gilead: Honoraria; Celgen/BMS: Honoraria; Roche: Honoraria, Research Funding. Rambaldi:Amgen: Honoraria; Pfizer: Honoraria; Astellas: Honoraria; ABBVIE: Honoraria; Jazz: Honoraria; Kite-Gilead: Honoraria; Novartis: Honoraria; Incyte: Honoraria; Roche: Honoraria; Janssen: Honoraria; Celgene-BMS: Honoraria; Omeros: Honoraria. Carrier:Pfizer: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy; BMS: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Leo Pharma: Consultancy, Honoraria, Research Funding. Ghia:MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Lilly/Loxo: Consultancy, Honoraria. Stamatopoulos:Janssen: Research Funding; AbbVie: Research Funding.